Leerink Partnrs Forecasts Bruker's Q4 Earnings (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR - Free Report) - Equities researchers at Leerink Partnrs lowered their Q4 2024 earnings estimates for shares of Bruker in a report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.73 for the quarter, down from their previous forecast of $0.95. The consensus estimate for Bruker's current full-year earnings is $2.61 per share. Leerink Partnrs also issued estimates for Bruker's Q1 2025 earnings at $0.54 EPS, Q2 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.90 EPS, FY2025 earnings at $2.73 EPS, Q1 2026 earnings at $0.70 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $3.22 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. During the same period last year, the firm posted $0.74 EPS. The business's quarterly revenue was up 16.4% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on the stock. Citigroup cut their price objective on shares of Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday. Wells Fargo & Company dropped their price target on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday. TD Cowen decreased their price objective on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a report on Wednesday. Barclays dropped their target price on Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a report on Wednesday. Finally, Wolfe Research lowered Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $79.36.

Bruker Stock Performance

BRKR stock traded down $2.76 during trading on Friday, reaching $57.73. 1,077,381 shares of the company's stock were exchanged, compared to its average volume of 1,072,928. Bruker has a 1-year low of $54.55 and a 1-year high of $94.86. The firm has a market cap of $8.74 billion, a PE ratio of 23.95, a P/E/G ratio of 2.32 and a beta of 1.20. The company's fifty day moving average price is $63.83 and its 200-day moving average price is $66.47. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18.

Institutional Investors Weigh In On Bruker

Institutional investors and hedge funds have recently modified their holdings of the stock. TD Asset Management Inc increased its stake in Bruker by 7.4% in the 1st quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company's stock worth $168,036,000 after purchasing an additional 123,984 shares in the last quarter. Atria Investments Inc purchased a new position in shares of Bruker in the first quarter worth approximately $1,142,000. Point72 Asset Management L.P. acquired a new stake in shares of Bruker during the second quarter valued at approximately $36,472,000. Epoch Investment Partners Inc. lifted its position in shares of Bruker by 15.2% in the 1st quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company's stock valued at $43,857,000 after acquiring an additional 61,429 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Bruker by 1,694.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company's stock worth $12,936,000 after purchasing an additional 191,435 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.